Immune checkpoint inhibitors in cancer therapy.

about

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis.

P2860

Q49242745-A27661D9-2177-4E6A-ADDA-71FB6042B9E9

P2860

Immune checkpoint inhibitors in cancer therapy.

Item

http://www.wikidata.org/entity/Q45871487

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Immune checkpoint inhibitors in cancer therapy.

@en

Immune checkpoint inhibitors in cancer therapy.

@nl

type

Item

label

Immune checkpoint inhibitors in cancer therapy.

@en

Immune checkpoint inhibitors in cancer therapy.

@nl

prefLabel

Immune checkpoint inhibitors in cancer therapy.

@en

Immune checkpoint inhibitors in cancer therapy.

@nl

P1476

Immune checkpoint inhibitors in cancer therapy.

@en

P2093

Eika S Webb

http://www.w3.org/2001/XMLSchema#string

Ming Yuan

http://www.w3.org/2001/XMLSchema#string

Nicholas R Lemoine

http://www.w3.org/2001/XMLSchema#string

Peng Liu

http://www.w3.org/2001/XMLSchema#string

Renato Baleeiro

http://www.w3.org/2001/XMLSchema#string

Yao-He Wang

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

Cancer; a biological approach. I. The processes of control

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence

P31

scholarly article

P356

10.7555/JBR.31.20160168

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28866656

http://www.w3.org/2001/XMLSchema#string

P932

6163118

http://www.w3.org/2001/XMLSchema#string

Immune checkpoint inhibitors in cancer therapy.

about

P2860

P2860

Immune checkpoint inhibitors in cancer therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P932